Pfizer's cost-cutting drives Q3 profit as sales fall by 3%
This article was originally published in Scrip
With only two of its top 10 pharmaceutical products achieving sales growth, Pfizer's third-quarter revenues fell by 3% to $11.6 billion. Competition from generic versions of its products and a $610 million hole carved out of revenues by the effect of the dollar strengthening against other currencies were the main factors behind the top-line decline.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.